Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Assets: 2019-2024

Historic Non-Current Assets for Revolution Medicines (RVMD) over the last 6 years, with Dec 2024 value amounting to $230.7 million.

  • Revolution Medicines' Non-Current Assets rose 49.26% to $274.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.4 million, marking a year-over-year increase of 49.26%. This contributed to the annual value of $230.7 million for FY2024, which is 26.45% up from last year.
  • According to the latest figures from FY2024, Revolution Medicines' Non-Current Assets is $230.7 million, which was up 26.45% from $182.4 million recorded in FY2023.
  • In the past 5 years, Revolution Medicines' Non-Current Assets registered a high of $230.7 million during FY2024, and its lowest value of $113.3 million during FY2020.
  • In the last 3 years, Revolution Medicines' Non-Current Assets had a median value of $182.4 million in 2023 and averaged $188.3 million.
  • Data for Revolution Medicines' Non-Current Assets shows a peak YoY soared of 30.89% (in 2020) over the last 5 years.
  • Revolution Medicines' Non-Current Assets (Yearly) stood at $113.3 million in 2020, then skyrocketed by 30.84% to $148.2 million in 2021, then grew by 2.38% to $151.7 million in 2022, then grew by 20.22% to $182.4 million in 2023, then grew by 26.45% to $230.7 million in 2024.